Analgesics combined with naturally-occurring chondroprotective agents

• US 20010046971A1
• Filed: 02/15/2001
• Published: 11/29/2001
• Est. Priority Date: 02/18/2000
• Status: Active Grant

• Current Assignee: Milton Hammerly
• Original Assignee: Milton Hammerly
• Inventors: Hammerly, Milton
• Granted Patent: US 6,608,041 B2
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/7008 Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence

Abstract

Provided herein are medicinal compositions of matter that comprise a chondroprotective component and an analgesic component, wherein the chondroprotective component is naturally occurring in a preferred form of the invention, and the analgesic component is acetaminophen or its derivatives or analogs. The invention also provides procedures for administering the compositions to a patient who is afflicted with osteoarthritis.

Claims

1. A medicinal composition useful in the treatment of osteoarthritis comprising:

a) an analgesic component; and

b) a chondro-protective agent component.

2. A composition as set forth in

claim 1

wherein said analgesic component comprises a compound selected from the group consisting of:

acetaminophen, an acetaminophen derivative, or an acetaminophen analog.

3. A composition as set forth in

claim 1

wherein said chondro-protective agent is naturally-occurring.

4. A composition as set forth in

claim 1

wherein said chondro-protective agent comprises a glycosaminoglycan.

5. A composition as set forth in

claim 1

wherein said chondro-protective agent comprises at least one compound selected from the group consisting of:

glucosamine sulfate, chondroitin sulfate, N-acetyl glucosamine, hyaluronic acid and hyaluronan.

6. A composition according to

claim 1

wherein said analgesic component is present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween.

7. A composition according to

claim 1

wherein said chondro-protective component is present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween.

8. A composition according to claims 1 wherein said composition is prepared by cocomminutation of said chondro-protective agent with said analgesic component.

9. A composition according to

claim 1

wherein the analgesic component is a compound selected from the group consisting of:

acetaminophen, an acetaminophen derivative, or an acetaminophen analog, said analgesic component being present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween, and wherein said chondro-protective agent component is selected from the group consisting of glucosamine sulfate, chondroitin sulfate, N-acetyl glucosamine, hyaluronic acid and hyaluronan, and wherein said chondro-protective component is present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween.

10. A composition according to

claim 1

wherein the analgesic component is acetaminophen and is present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween, and wherein said chondro-protective agent component is selected from the group consisting of:

glucosamine sulfate, chondroitin sulfate, N-acetyl glucosamine, hyaluronic acid and hyaluronan, and wherein said chondro-protective component is present in any amount between 0.05% and 99.5% by weight based upon the total weight of the composition, including every hundredth percentage therebetween.

11. A process for treating osteoarthritis comprising the steps of:

a) providing a composition according to

claim 1

; and

b) introducing said composition into a human body that is afflicted with osteoarthritis.

12. A process according to

claim 11

further comprising the step of:

c) repeating step b) at least one times per day for a period of at least 3 weeks.

13. A process for treating osteoarthritis comprising the steps of:

a) providing a composition according to

claim 9

; and

b) introducing said composition into a human body that is afflicted with osteoarthritis.

14. A process according to

claim 13

further comprising the step of

c) repeating step b) at least one times per day for a period of at least 3 weeks.

15. A process for treating osteoarthritis comprising the steps of:

a) providing a composition according to

claim 10

; and

b) introducing said composition into a human body that is afflicted with osteoarthritis.

16. A process according to

claim 15

further comprising the step of:

c) repeating step b) at least one times per day for a period of at least 3 weeks.

17. The process according to

claim 11

wherein said composition contains a therapeutically effective therapeutic amount of chondro-protective agent component.

18. The process according to

claim 11

wherein said composition contains a therapeutically effective therapeutic amount of analgesic component.

19. A process according to

claim 11

wherein said introducing is undertaken orally, buccally, intravenously, intramuscularly, parenterally, or sublingually.

20. A process for treating osteoarthritis comprising the step of simultaneously introducing a therapeutically effective amount of an analgesic and a therapeutically effective amount of a naturally-occurring chondroprotective agent to a mammalian subject.